A CASE CLINICAL ANALYSIS AND PHARMACEUTICAL CARE OF PERIPHERAL NEUROPATHY INDUCED BY BORTEZOMIB IN A PATIENT WITH MULTIPLE MYELOMA
Objective This study aims to investigate the case of peripheral neuropathy in a patient with multiple myeloma undergoing bortezomib chemotherapy,with the involvement of a clinical pharmacist.The study focuses on understanding the pathogenesis and treatment process.Methods Systematic searches across multiple databases and extensive literature review were conducted to analyze the pathogenesis and risk factors of bortezomib-induced peripheral neuropathy.Patient-specific treat-ment plans for peripheral neuropathy in multiple myeloma were clinically analyzed,considering physical examination,blood tests,biochemical assessments,medical history,and symptoms.A comprehensive pharmaceutical care plan was devised.Results Combining information from the patient's physical examination,routine blood tests,biochemical assessments,medical history,and symptoms,an individualized treatment plan for bortezomib-induced peripheral neuropathy in multiple myeloma was clinical-ly analyzed.Clinical pharmacists actively participated in the development of a personalized pharmaceutical care plan,which,when implemented by clinicians,led to the improvement of the patient's drug-induced peripheral neuropathy.Conclusion Pe-ripheral neuropathy induced by bortezomib in patients with multiple myeloma is an adverse reaction that can be treated and re-versed.Through timely adjustments to the medication regimen,symptoms and the progression of the disease in the patient can be significantly alleviated or delayed,and in some cases,even reversed.The involvement of clinical pharmacists in the treatment pro-cess plays a crucial role by assisting physicians in formulating more personalized treatment plans,providing robust support for the safe,effective,and rational use of medication for the patient.
万方数据
维普
